6 July - MHRA and UK Space Agency Establish the World's First Regulatory Pathway for In-Orbit Pharmaceutical Manufacturing — Roadmap Due Autumn 2026

The UK has published the world's first regulatory pathway for space-manufactured medicines. Learn what the MHRA and UK Space Agency announced and what it means for regulatory professionals.

The meeting point between the global space economy and the pharmaceutical industry has been building for decades. Since the first protein crystallisation experiments aboard the International Space Station (ISS) in the early 2000s, researchers have understood that microgravity — the near-weightless environment found in low Earth orbit — offers conditions that simply cannot be replicated on Earth. Without the pull of gravity, sedimentation and mechanical stress are absent, allowing biological molecules to form more uniform and more ordered structures.

For the pharmaceutical industry, this translates into tangible gains: larger, purer protein crystals that yield better structural data for drug design; more precisely formulated biologics with improved solubility and stability; and the potential to manufacture monoclonal antibodies, vaccines and insulin analogues with enhanced quality attributes. Evidence from almost 500 biopharma experiments on the ISS has built a compelling scientific case for the potential of microgravity in drug development and manufacturing. However, the regulatory landscape has not kept pace.

Until March 2026, no health authority anywhere in the world had published a dedicated regulatory pathway clarifying how Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), marketing authorisation requirements and supply chain obligations would apply to a medicine manufactured, in whole or in part, in orbit. That absence created a fundamental barrier: pharmaceutical companies and space biotech firms could not commit investment to in-orbit manufacturing programmes if they could not foresee a clear route to patient access.

1. At a Glance

2. Background: Why Regulating Pharmaceutical Manufacturing Beyond Earth Could Not Wait

3. The March 2026 Announcement: A Coordinated Regulatory Package

4. The Microgravity Advantage: How Space Conditions Transform Drug Manufacturing

5. How UK Regulatory Frameworks Apply to In-Orbit Production

6. The Autumn 2026 Roadmap and the UK's Global Regulatory Leadership

7. Deepen Your Knowledge: Regulatory Affairs Training on This Topic

8. Practical Implications for Regulatory Affairs Professionals

9. Key Takeaways

10. Take the Next Step in Your Regulatory Affairs Career

11. Frequently Asked Questions

12. Further Reading and Reference Sources

At a Glance

- On 5 March 2026, the UK Space Agency, MHRA, Regulatory Innovation Office (RIO) and Civil Aviation Authority (CAA) jointly published the world's first dedicated regulatory pathway for medicines manufactured in orbit, alongside a coordinated package of regulatory guidance, case studies and a re-entry regulatory sandbox.

- The announcement was made at Space-Comm Expo, ExCeL London, and links directly to the UK Government's £2 billion Life Sciences Sector Plan.

- A full collaborative regulatory roadmap, mapping a generic end-to-end in-orbit manufacturing lifecycle against existing UK regulatory frameworks, is due to be published in Autumn 2026.

- The MHRA is applying its 2025 Decentralised Manufacture and Point of Care (DCM/POC) legislative framework — originally developed for point-of-care and modular manufacturing on Earth — as the regulatory foundation for in-orbit production.

- BioOrbit, a UK start-up designing a scalable system to crystallise biologic drugs for cancer treatments in microgravity, has received a £250,000 feasibility study funded through the UK Space Agency's Unlocking Space Portfolio; the study includes collaborative regulatory pathway work with the MHRA.

- The sector is estimated to generate between $2.8 billion and $4.2 billion in revenues as commercial in-orbit pharmaceutical development matures.

- This is a UK-only (MHRA) initiative — neither the European Medicines Agency (EMA) nor the US Food and Drug Administration (FDA) has published a comparable dedicated framework at this time.

Background: Why Regulating Pharmaceutical Manufacturing Beyond Earth Could Not Wait

The current situation developed against a backdrop of rapid change in both the commercial space sector and UK pharmaceutical regulation. The dramatic reduction in launch costs driven by providers such as SpaceX and Blue Origin, alongside the growth of commercial free-flyer satellites and orbital laboratories, has transformed access to microgravity from a government-only endeavour to a commercially viable proposition.

In parallel, the UK's post-Brexit regulatory independence created conditions for the MHRA to move faster and with greater flexibility than a multi-member regulatory bloc. The MHRA's 2025 Decentralised Manufacture and Point of Care (DCM/POC) legislation — a world-first framework for medicines manufactured outside traditional fixed-site facilities — provided a direct regulatory analogy for in-orbit production: both contexts involve automation, remote oversight, constrained manufacturing environments and atypical distribution pathways.

The Space Industry Act 2018 and Outer Space Act 1986 already provided the legal basis for licensing spaceflight activities, and in June 2025 Space Forge's ForgeStar 1 became the UK's first in-orbit manufacturing platform to be licensed by the CAA — setting a practical precedent. By early 2026, the regulatory community, the space sector and the biopharma industry had built enough mutual understanding, and enough political will, to formalise a coordinated approach.

Understanding how novel manufacturing environments interact with existing GMP, GDP and marketing authorisation obligations is a core component of the Entry to Regulatory regulatory affairs training programme, which covers UK MHRA regulatory frameworks and advanced manufacturing regulation as part of its practical curriculum for EU, UK and US regulations — see the full course details at https://pages.entrytoregulatory.com/courses/

The March 2026 Announcement: A Coordinated Regulatory Package

On 5 March 2026, at Space-Comm Expo, one of Europe's largest space industry gatherings, held at ExCeL London, the UK government unveiled its coordinated package for in-orbit pharmaceutical manufacturing (IOM). The announcement was made jointly by the UK Space Agency, the Medicines and Healthcare products Regulatory Agency (MHRA), the Regulatory Innovation Office (RIO) — a body within the Department for Science, Innovation and Technology (DSIT) established in October 2024 to tackle regulatory barriers to emerging technologies — and the Civil Aviation Authority (CAA), which acts as the UK's space regulator under the Space Industry Act 2018. Two documents were published simultaneously:

1. A GOV.UK press release — "UK sets out world-leading pathway for space-manufactured drugs" — setting out the scope and strategic context of the initiative.

2. A joint statement from the UK Space Agency, MHRA, RIO and CAA — providing operational detail on how the four bodies will coordinate, what regulatory tools are being developed, and how companies should engage.

The package announced on 5 March 2026 comprises four key elements:

- Regulatory guidance and joint case studies: The MHRA and UK Space Agency are producing principles-based case studies illustrating the regulatory route from in-orbit manufacture to patient access, covering space biotech, pharmaceutical and biopharma companies.

- Early scientific and regulatory advice: Companies can access MHRA's Scientific and Regulatory Advice services and the MHRA Innovation Accelerator to receive structured guidance on product development, manufacturing models and evidential requirements in the context of microgravity manufacturing.

- A Re-entry Regulatory Sandbox: The CAA and government are launching a dedicated regulatory sandbox for re-entry activities associated with in-orbit manufacturing, building on the learnings from the Rendezvous and Proximity Regulatory Sandbox.

- Strengthened supply-chain engagement: The UK Space Agency is engaging with the NHS and the biopharma supply chain to build demand and identify barriers along the adoption pathway.

The package sits within the broader ambitions of the UK Government's £2 billion Life Sciences Sector Plan and the Modern Industrial Strategy 2025, with In-Orbit Servicing, Assembly and Manufacturing (ISAM) formally identified as one of four Ministerial priorities for space.

The Microgravity Advantage: How Space Conditions Transform Drug Manufacturing

Microgravity — the near-absence of gravity experienced in low Earth orbit — alters the physical behaviour of biological and chemical systems in ways that have profound implications for pharmaceutical manufacturing. Without sedimentation, convection currents or gravity-driven mechanical stress, molecules can interact and self-organise with greater precision. The MHRA and UK Space Agency's joint statement identifies four principal pharmaceutical advantages of microgravity conditions:

1. Better drug formulations: Complex medicines, such as biologics that currently require hospital intravenous administration, may be reformulated as subcutaneous injections suitable for home use, reducing cost and improving patient quality of life.

2. Improved protein crystals: More uniform, purer crystal structures can be produced in microgravity compared to Earth-based conditions, potentially optimising the performance, stability and dosing of protein-based medicines.

3. Advanced and personalised therapies: Scientists can grow more realistic organoids and organ-on-a-chip systems in microgravity, enabling personalised treatments and new approaches to oncology research.

4. Earth-based manufacturing improvements: Discoveries made and validated in space have downstream value for reformulating and improving how drugs are manufactured and delivered on Earth.

For the biopharma industry, the strategic advantages are equally important. The microgravity environment is particularly relevant for biologics — including monoclonal antibodies (mAbs), vaccines and insulin — which are difficult to crystallise with sufficient uniformity using terrestrial processes. Start-up BioOrbit is one of the most advanced UK companies working in this space. Funded through a £250,000 feasibility study under the UK Space Agency's Unlocking Space Portfolio, BioOrbit is designing a scalable in-orbit manufacturing system to crystallise biologic drugs intended for cancer treatment. BioOrbit was also supported through the UK Space Agency Accelerator programme.

Regulatory professionals looking to deepen their understanding of novel biological manufacturing approaches and their regulatory implications will find relevant practical training in the Entry to Regulatory course, which includes hands-on assignments covering CMC regulatory submissions, biologic medicines regulation and marketing authorisation strategy as part of its UK and EU regulatory curriculum. Full details at https://pages.entrytoregulatory.com/courses/

How UK Regulatory Frameworks Apply to In-Orbit Production

A fundamental question for any company considering in-orbit pharmaceutical manufacturing has been whether existing UK medicines regulations apply, and if so, how. The MHRA's position, confirmed in both the March 2026 joint statement and the June 2026 MedRegs blog post, is unambiguous: existing UK medicines regulations — including GMP, GDP and marketing authorisation requirements — do apply to medicines manufactured in orbit for patient use, with risk-based, proportionate approaches applied to novel factors specific to the in-orbit context.

The MHRA is drawing directly on its experience from the 2025 Decentralised Manufacture and Point of Care (DCM/POC) legislation — a world-first framework for regulating medicines manufactured across decentralised and constrained settings, which addressed automation, remote oversight and limited human intervention. These are precisely the conditions encountered in in-orbit manufacturing. The Agency is also leveraging the model of the Regulatory Advice Service for Regenerative Medicine (RASRM), which demonstrated the value of early, structured regulatory engagement with innovators to iteratively refine approaches before formal submission.

In practice, the MHRA's approach to in-orbit manufacturing involves three interconnected workstreams:

- Early engagement: Directly advising biopharma companies, space platform providers and engineering biology innovators on product development, manufacturing models and evidentiary requirements — before formal regulatory submissions are made.

- GMP and GDP application: Assessing how existing GMP and GDP frameworks apply to in-orbit production, including novel considerations such as payload logistics, the space environment and re-entry procedures.

- Adaptive testing mechanisms: Working with partners to explore whether novel manufacturing concepts can be tested and refined in a controlled regulatory setting — analogous to a regulatory sandbox — before full submission.

The Civil Aviation Authority (CAA) has a complementary role. Under the Space Industry Act 2018 and Outer Space Act 1986, the CAA licenses spaceflight activities in the UK, including the operation of in-orbit manufacturing platforms. The CAA has confirmed that in-space manufacturing can be licensed under existing UK rules, provided that companies go through the normal approval process and demonstrate that risks are kept as low as reasonably practicable — including for the re-entry and safe landing of platforms carrying manufactured products.

The Autumn 2026 Roadmap and the UK's Global Regulatory Leadership

The most significant near-term development is the forthcoming collaborative regulatory roadmap, to be published jointly by the MHRA and the UK Space Agency in Autumn 2026. This document will be the most detailed guidance yet produced anywhere in the world on how to navigate the regulatory requirements for bringing a space-manufactured medicine to market. According to the MHRA's June 2026 MedRegs blog post, the roadmap will:

- Be based on a generic, end-to-end in-orbit manufacturing model

- Map each stage of the product lifecycle — from manufacturing in orbit through re-entry, quality testing, supply chain and regulatory submission — against existing UK regulatory frameworks

- Identify applicable requirements at each stage, highlighting areas of regulatory overlap or uncertainty

- Signpost compliance pathways so that developers know exactly how to engage with each regulator and at what point

This end-to-end mapping approach will be particularly valuable for companies with no prior experience of the UK regulatory system, and for the many space technology companies that lack in-house pharmaceutical regulatory expertise.

The UK is simultaneously working to shape international regulatory standards for space-enabled biopharmaceutical manufacturing — a domain in which no global consensus yet exists. The inaugural UK-Swiss Microgravity Dialogue, held in June 2026, brought together experts and senior decision-makers from the space and pharmaceutical sectors for the first time to identify challenges and solutions for microgravity manufacturing and R&D. The UK has also indicated its intention to contribute to bilateral and multilateral engagement to encourage international regulatory alignment.

Government investment underpins this ambition. Alongside the BioOrbit feasibility study, the National Space Innovation Programme (NSIP) has invested approximately £2.2 million in grants supporting innovative in-orbit manufacturing technologies, including funding for Frontier Space Technologies (for their microgravity research SpaceLab), Biologic Technologies (for a "Space Biocomputer" to enable bio-manufacturing of RNA medicines), Imperial College London, the University of Glasgow and the University of Leicester. A £13 million UKI2S Space Portfolio — an evergreen pre-seed and seed stage fund — is also open to life science space companies seeking early-stage investment.

 Deepen Your Knowledge: Regulatory Affairs Training on This Topic

The MHRA and UK Space Agency's in-orbit pharmaceutical manufacturing initiative sits at the intersection of several advanced regulatory disciplines that are increasingly valued in the pharmaceutical and biotech sectors. For regulatory professionals, understanding this framework requires competence across multiple areas: the UK's GMP and GDP regimes as they apply to novel manufacturing settings; the MHRA's approach to marketing authorisation for advanced and biologic medicines; Chemistry, Manufacturing and Controls (CMC) strategy for biologics and other complex products; and the UK's distinctive post-Brexit regulatory architecture — including how it differs from the European Medicines Agency (EMA)'s frameworks. This is not a niche specialism: the principles underpinning in-orbit manufacturing regulation — risk-based GMP, decentralised production, novel distribution chains — are already reshaping how the MHRA approaches all advanced manufacturing, from point-of-care settings to modular facilities.

For life science graduates, career changers, pharmacy professionals and scientists seeking to move into regulatory affairs, developments like this one illustrate precisely why UK regulatory expertise is in high and growing demand. Companies entering the in-orbit pharmaceutical manufacturing space will need regulatory affairs professionals who understand not only the MHRA's core frameworks but also their application to novel, non-traditional manufacturing environments. Regulatory affairs professionals already working in CMC, biologics or manufacturing compliance will find this area of increasing practical relevance as the sector moves from feasibility study to commercialisation over the coming years.

The Introduction to Regulatory Affairs course at Entry to Regulatory directly addresses the knowledge areas that make a professional valuable in this emerging landscape. Its curriculum covers UK, EU and US pharmaceutical regulatory frameworks from the ground up — including GMP compliance, marketing authorisation pathways for advanced medicines, CMC regulatory submissions and the regulatory strategy considerations specific to novel and biological products. The course is equally suitable for those just entering the field and for experienced professionals looking to broaden or formalise their regulatory knowledge.

TRAINING SPOTLIGHT BOX:

Course: Introduction to Regulatory Affairs (Comprehensive Regulatory Affairs Course)

Provider: Entry to Regulatory

Relevant to this topic:

- UK pharmaceutical regulation and MHRA regulatory frameworks (including post-Brexit independence from EMA)

- Good Manufacturing Practice (GMP) and novel manufacturing compliance

- Marketing authorisation strategy for biological and advanced medicines

- Chemistry, Manufacturing and Controls (CMC) regulatory submissions

- Regulatory strategy for innovative, advanced therapy and novel-modality products

Format: Online, part-time | 6 hours per week | 3 months

Includes: Up to 3 months real work experience, job mentoring, CV review, mock interviews, industry-recognised certificate

Suitable for: Life science graduates, pharmacy professionals, career changers, scientists seeking regulatory transition

Start here: https://pages.entrytoregulatory.com/courses/

Practical Implications for Regulatory Affairs Professionals

Regulatory affairs professionals advising sponsors, manufacturers or space technology companies on in-orbit pharmaceutical manufacturing will face a new set of questions for which there is, as yet, limited established practice. The Autumn 2026 roadmap will provide significant clarity, but the immediate implications are already clear from the March 2026 joint statement and the June 2026 MHRA blog update. The table below summarises the most pressing practical questions and what has changed.

Key Takeaways

1. Engage with the MHRA now, before you have a submission. The MHRA and UK Space Agency have explicitly invited early engagement via Scientific and Regulatory Advice meetings and the MHRA Innovation Accelerator. Companies exploring in-orbit manufacturing should initiate contact at the earliest stage of product development — not when a submission is imminent.

2. Review your GMP and GDP strategy through the lens of novel manufacturing environments. Existing UK GMP and GDP frameworks apply in orbit; sponsors must assess how standard requirements translate to in-orbit conditions, including payload constraints, automated manufacturing, remote oversight and non-standard distribution pathways.

3. Monitor the Autumn 2026 roadmap publication closely. The MHRA/UK Space Agency collaborative roadmap will be the most detailed guidance document on this topic in the world. Regulatory teams should prepare to review it on publication and assess whether product development programmes require adjustment.

4. Register for the Re-entry Regulatory Sandbox if developing a platform involving product return. The CAA's Re-entry Regulatory Sandbox is being designed for in-orbit manufacturing re-entry activities. Companies whose programmes involve returning space-manufactured products to Earth should engage with the CAA proactively — contact is available via commercialspaceflight@caa.co.uk.

5. Distinguish UK (MHRA) and EU (EMA) requirements explicitly. There is no EMA equivalent of this pathway. Sponsors seeking both UK marketing authorisation and EU marketing authorisation for the same in-orbit manufactured product will need to manage two separate regulatory processes; the EMA has not yet clarified its position on in-orbit manufacturing.

6. Track international developments, particularly UK-Swiss and broader multilateral engagement. The inaugural UK-Swiss Microgravity Dialogue in June 2026 signals that international regulatory alignment is being actively pursued. Regulatory professionals should monitor whether bilateral agreements produce convergent standards — which could simplify multi-market development programmes.

7. Build CMC regulatory expertise in biologics and novel manufacturing now. The companies and professionals who will be best placed to capitalise on the in-orbit pharmaceutical manufacturing opportunity are those who combine deep CMC knowledge with an understanding of the MHRA's advanced manufacturing frameworks. This is a career-defining specialisation in the making.

Take the Next Step in Your Regulatory Affairs Career

The MHRA and UK Space Agency's in-orbit pharmaceutical manufacturing initiative is a vivid illustration of how rapidly the boundaries of regulatory affairs are expanding. Professionals who understand not only the foundational frameworks — GMP, marketing authorisation, CMC, pharmacovigilance — but also how those frameworks apply to novel, emerging manufacturing environments, are precisely the people that pharmaceutical, biotech and space technology companies will need as this sector grows from feasibility studies to commercial reality.

Understanding how frameworks like the MHRA's novel manufacturing regulations, the Space Industry Act 2018 and advanced biologic medicine pathways interact is not a specialism reserved for those already deep in the industry. It is accessible to any motivated person who invests in solid, practical regulatory affairs training. Whether you are a life science graduate looking to break in, a pharmacist or scientist considering a career transition, or an experienced professional ready to deepen your expertise, the Introduction to Regulatory Affairs course at Entry to Regulatory gives you the knowledge, real work experience and career support to move forward — at your own pace, online, in just six hours a week.

Explore the full course details and register for a free introductory webinar at Entry to Regulatory: https://pages.entrytoregulatory.com/courses/

Frequently Asked Questions

What is in-orbit pharmaceutical manufacturing?

In-orbit pharmaceutical manufacturing (IOM) is the production of medicines, or components of medicines, in the microgravity environment of low Earth orbit — aboard platforms such as the International Space Station (ISS), commercial free-flyer satellites or dedicated orbital laboratories. Microgravity enables higher-quality protein crystal formation, improved drug formulation and more precisely structured biologics that cannot be achieved through terrestrial manufacturing. The goal is to produce medicines that are more stable, more effective and potentially suitable for simplified delivery — for example, at-home injection instead of hospital intravenous infusion.

What did the UK announce on 5 March 2026?

On 5 March 2026, the UK Space Agency, MHRA, Regulatory Innovation Office (RIO) and Civil Aviation Authority (CAA) published the world's first dedicated regulatory pathway for space-manufactured medicines, alongside a joint statement and a coordinated package including regulatory guidance, principles-based case studies, a Re-entry Regulatory Sandbox and strengthened supply-chain engagement with the NHS and biopharma sector. A full collaborative regulatory roadmap is due in Autumn 2026. The announcement was made at Space-Comm Expo, ExCeL London, and is part of the UK Government's £2 billion Life Sciences Sector Plan.

Does the EU (EMA) have an equivalent regulatory pathway for in-orbit pharmaceutical manufacturing?

No. As of the date of this article, the European Medicines Agency (EMA) has not published a comparable dedicated regulatory framework for in-orbit pharmaceutical manufacturing. This is a UK-specific MHRA initiative, enabled in part by the UK's regulatory independence following its departure from the EU. Sponsors seeking both UK and EU marketing authorisations for in-orbit manufactured medicines will need to engage with each authority separately and cannot assume that the MHRA's pathway will be recognised or mirrored by the EMA.

How does the MHRA's GMP framework apply to medicines manufactured in space?

The MHRA has confirmed that existing UK GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) requirements apply to medicines manufactured in orbit for patient use. The Agency applies a risk-based, proportionate approach to novel factors specific to the in-orbit environment — such as payload constraints, automated processes, remote oversight and non-standard re-entry and distribution procedures. The MHRA's 2025 Decentralised Manufacture and Point of Care (DCM/POC) legislation, which already addressed automated and constrained manufacturing settings, provides the primary regulatory analogy.

How can regulatory affairs training help me work in this area?

The in-orbit pharmaceutical manufacturing sector requires exactly the skills covered by structured regulatory affairs training: a thorough understanding of UK GMP and GDP, marketing authorisation strategy for biologics and advanced medicines, CMC regulatory submissions and the MHRA's approach to novel manufacturing. The Introduction to Regulatory Affairs course at Entry to Regulatory covers UK, EU and US pharmaceutical regulatory frameworks — including the MHRA's frameworks for novel manufacturing — and includes up to three months of real regulatory work experience and job search support. It is suitable for graduates, career changers and scientists at all stages. Start with a free introductory webinar at https://pages.entrytoregulatory.com/courses/

Next cohort starts: 12 July 2026. Limited spaces available. 

Further Reading and Reference Sources

[UK sets out world-leading pathway for space-manufactured drugs — UK Space Agency / MHRA / RIO / CAA, GOV.UK press release](https://www.gov.uk/government/news/uk-sets-out-world-leading-pathway-for-space-manufactured-drugs)

Published: 5 March 2026

[Joint Statement from the UK Space Agency, MHRA, RIO and CAA — GOV.UK](https://www.gov.uk/government/news/joint-statement-from-the-uk-space-agency-the-medicines-and-healthcare-products-regulatory-agency-the-regulatory-innovation-office-and-the-civil-avia)

Published: 5 March 2026

[The Next Frontier: Unlocking In-Orbit Manufacturing of Medicines — MHRA MedRegs Blog, GOV.UK](https://medregs.blog.gov.uk/2026/06/25/the-next-frontier-unlocking-in-orbit-manufacturing-of-medicines/)

Published: 25 June 2026

[UK regulation of in-orbit pharmaceutical manufacturing — DLA Piper (Poppy Williams and Taryn Jones)](https://www.dlapiper.com/en-us/insights/blogs/environment-health-safety-and-product-compliance/2026/uk-regulation-of-in-orbit-pharmaceutical-manufacturing)

Published: 24 March 2026

[UK sets out pathway for medicines manufactured in orbit — Regulatory Quality Associates (RQA)](https://www.therqa.com/news/uk-sets-out-pathway-medicines-manufactured-orbit/)

Published: March 2026

[Joint statement from the UK Space Agency, MHRA, the Regulatory Innovation Office and the Civil Aviation Authority — RQA detailed commentary](https://www.therqa.com/news/joint-statement-uk-space-agency-mhra-regulatory-in/)

Published: March 2026

[From Insight to Implementation: A Year of Progress in Microgravity R&D — Satellite Applications Catapult](https://sa.catapult.org.uk/blogs/from-insight-to-implementation-a-year-of-progress-in-microgravity-rd/)

Published: March 2026

[Creating New and Better Drugs with Protein Crystal Growth Experiments — NASA](https://www.nasa.gov/missions/station/iss-research/creating-new-and-better-drugs-with-protein-crystal-growth-experiments/)

Published: Updated 2024

About the Author: Rabiea is an Honorary Associate Professor at UCL, former MHRA Health Authority reviewer, and CEO of Entry to Regulatory and Advanced Regulatory Consulting. After transitioning from retail pharmacy to regulatory affairs, she has dedicated her career to helping others make the same successful career change. Connect with her on LinkedIn for the latest regulatory affairs insights and career advice.  

Disclaimer

This article is provided for informational purposes only. Regulatory guidance, legislative instruments and health authority policies evolve frequently. Always consult the most current official publications from the relevant health authority — including the MHRA, UK Space Agency and Civil Aviation Authority — and seek qualified professional regulatory advice for specific product development, submission or compliance decisions. Entry to Regulatory training courses are designed for educational and career development purposes.